Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of radiolabelled somatostatin analogues

• Unité de recherche: INNOSUISSE
• Numéro de projet: 18282.2 PFLS-LS
• Titre du projet anglais: Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of radiolabelled somatostatin analogues

Description succincte (Allemand)

Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron|Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of|radiolabelled somatostatin analogues

Description succincte (Anglais)

Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of radiolabelled somatostatin analogues

Résumé des résultats (Abstract) (Allemand)

The project targets the development of the novel somatostatin (SST) analogue G02113, with high affinity to|the SST receptor subtypes 2 and 5, as a theranostic agent for the management of patients suffering|from neuroendocrine tumours (NETs). G02113 labelled with 68Ga will be developed as a Positron Emission|Tomography (PET) imaging tracer for diagnostic imaging and therapy follow-up of NETs, while the same|compound labelled with 177Lu will be developed as a therapeutic agent for Peptide Receptor Radionuclide|Therapy (PRRT).

Résumé des résultats (Abstract) (Anglais)

The project targets the development of the novel somatostatin (SST) analogue G02113, with high affinity to|the SST receptor subtypes 2 and 5, as a theranostic agent for the management of patients suffering|from neuroendocrine tumours (NETs). G02113 labelled with 68Ga will be developed as a Positron Emission|Tomography (PET) imaging tracer for diagnostic imaging and therapy follow-up of NETs, while the same|compound labelled with 177Lu will be developed as a therapeutic agent for Peptide Receptor Radionuclide|Therapy (PRRT).